Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | FADS1 | O60427 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19368884 | 0.84 | KCNH2 (0.42) | LRRK2KCNH2BRD4CREBBPEPHB4 | |
| SCHEMBL25315734 | 0.83 | KCNH2 (0.50) | LRRK2KCNH2BRD4CREBBPL3MBTL1 | |
| SCHEMBL17806566 | 0.83 | EP300 (0.41) | LRRK2KCNH2BRD4CREBBPL3MBTL1 | |
| SCHEMBL15782893 | 0.82 | FFAR1 (0.51) | LRRK2TTK | |
| SCHEMBL17809809 | 0.79 | LRRK2 (0.64) | LRRK2KCNH2CREBBPKDREPHB4 | |
| SCHEMBL19537429 | 0.79 | KDM5A (0.46) | LRRK2KCNH2FADS1TTK | |
| SCHEMBL11918420 | 0.78 | AR (0.38) | LRRK2FADS1HDAC4 | |
| SCHEMBL18985800 | 0.76 | MEN1 (0.42) | LRRK2KCNH2BRD4CREBBPTTK | |
| SCHEMBL25322449 | 0.76 | FFAR1 (0.53) | LRRK2KCNH2BRD4CREBBP | |
| SCHEMBL13036117 | 0.76 | PIK3CD (0.51) | LRRK2KCNH2KDREPHB4TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3224258-B1 | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | LRRK2 1250/4885KCNH2 2291/4885BRD4 11/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | LRRK2 1250/4885KCNH2 2291/4885BRD4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.